The external glycoproteins of human immunodeficiency virus type 1 (HIV-I) (gpl20) and HIV-2 (gpl05) are responsible for binding the cellular receptor CD4. The proteins are functionally identical although their affinity for CD4 varies, with gpl20 binding 10-to 20-fold more efficiently than gpl05. To investigate the structural requirements for CD4 binding in each molecule we have constructed a number of hybrid glycoproteins in which sequences are exchanged between the two molecules via conserved residues and subsequently tested for their ability to bind to CD4. We found that two constructs in which the V1/V2 or V3 loops of gpl05 are exchanged for those of gpl20 continue to bind to CD4. Surprisingly, however, all other domain exchange mutants failed to bind to CD4 suggesting that long-range interactions within the molecule are sequence-specific. Mixing mutant molecules in vitro did not rescue CD4 binding. However, coexpression of a number of mutant glycoprotein pairs within the same cell produced complementation of CD4 binding ability; complementing molecules were shown to be heteromeric in structure. Alignment of the molecules within each complementation group allowed the interactive sequences necessary for receptor binding to be determined. These sequences constitute a novel target for the disruption of gpl20 function.
Introduction
The external glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-2 are widely divergent (approximately 409/0 sequence identity) but can be aligned by virtue of 19 conserved cysteine residues (Guyader et al., 1987) . The disulphide bonding pattern for HIV-1 gp 120 has been formally determined (Leonard et al., 1990 ) and an equivalent model has been suggested for HIV-2 gpl05 (Wolf et al., 1991; Hoxie, 1991) . Although the molecules are functionally similar they are phenotypically marked by their CD4 binding efficiencies (Moore, 1990; Looney et al., 1990; Moore et al., 1991; Hoxie, 1991) , a property that appears to vary amongst HIV strains (Ivey-Hoyle et al., 1991) . The sequence arrangement within each molecule is similar; five relatively conserved (C) sections of sequence are interspersed with five highly variable (V) regions (Modrow et al., 1987) and it seems reasonable to suppose that the conserved regions represent sequences required t Present address: The Aaron Diamond AIDS Research Center, 455 First Avenue, 7th Floor, New York, New York 10016, U.S.A.
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for biological activity (CD4 and gp41 binding) whereas the variable regions illustrate the regions of the molecule that can change in response to sequence variation and antibody pressure. Mutagenesis experiments to date support this model; point mutations within the variable regions tend not to affect CD4 or gp41 binding whereas those in the conserved regions of the molecule do (Dowbenko et al., 1988; Cordonnier et al., 1989; Olshevsky et al., 1990) . Within the conserved sequences, mutations that cluster in the C-terminal third of the molecule (domains C3 and C4) affect CD4 binding the most although mutations in the N-terminal region of the molecule affecting CD4 binding have also been reported (Olshevsky et al., 1990; Syu et al., 1990) .
As the organizational features and biological activity of gpl20 and gpl05 are shared, we considered that domain exchange between the two molecules might be possible. In particular, hybrid molecules in which sequences of the two glycoproteins were exchanged between conserved cysteine residues known to form disulphide pairs, might allow the subdomains of the molecule necessary for CD4 binding to be determined. Here we describe the construction and properties of a number of such domain exchange mutants.
Methods

Mutagenesis and expression.
In all cases the recipient molecule for mutagenesis was the HIV-2RoD gpl05 gene cloned into the singlestranded transfer vector pAcCL29-1 (Livingstone & Jones, 1989; Morikawa et al., 1990) . HIV-1 gpl20 fragments for transposition were generated by polymerase chain reaction (PCR) from a proviral clone of HIV-ILAv gpl20 as described (Clackson & Winter, 1989) . The sequences of the oligonucleotides used for each PCR are not listed here but are available from the authors. All sticky feet (SF) primers were 50 nucleotides in length and spanned the cysteine residue conserved between gpl20 and gpl05. In all cases, 20 bases at the 3' end of the oligonucleotide were homologous to the HIV-1 sequence and 30 bases at the 5' end (the sticky foot) were homologous to the HIV-2 sequence. Conditions for mutagenesis were as described (Clackson & Winter, 1989) except that the amount of T4 DNA ligase in the reaction was reduced from 400 units to 10. Mutation frequencies varied from 5 to 80 % of progeny clones and all SF mutants were confirmed by sequence analysis prior to their use for expression. Recombinant baculoviruses were selected by standard (Summers & Smith, 1987) or, latterly, by improved procedures (Kitts et al., 1991) , plaque-purified and grown to high titre before use in expression studies.
Infections andprotein analysis. Recombinant baculoviruses were used to infect Spodoptera frugiperda (Sf9) cells at a multiplicity of approximately 10. Cells and supernatants were harvested at 2 days post-infection for Western blot analysis (Burnette, 1981) or CD4 binding assay. Antigen in the supernatant was normalized by a semiquantitative Western blot using a mixture of D7324 and D7335 (Aalto Bio Reagents) each at 1 Ixg/ml. Soluble CD4 (sCD4) (Morikawa et al., 1990) binding was assessed by ELISA. The assay was as described (Moore, 1990) and, when the activity was titrated, the concentration of medium from infected cells was varied with a constant 2 ~tg/ml sCD4. SF mutant binding to cell surface CD4 was done by fluorescenceactivated cell sorting (FACS) assay as described (Fenouillet et al., 1990) 
Results
Mutagenesis and expression
Using SF-directed mutagenesis (Clackson & Winter, 1989) , we produced a series of hybrid glycoprotein genes ( Fig. 1) termed SF mutants (for nomenclature details see Fig. 1 ) and expressed all the resulting products in recombinant baculoviruses (Morikawa et al., 1990 . To confirm antigenically mixed proteins were expressed and secreted following recombinant virus production we used Western blotting assays (Burnette, 1981) with either HIV-1-or HIV-2-specific sera. In Fig. 2 two SF constructions, SF1,2 and SF3,4 (as examples), are compared to unmodified gpl20 or gpl05 expressed in the same system (Morikawa et al., 1990 . Both hybrids bind both antisera, as expected from the sequence exchanges made, whereas gpl20 or gpl05 react only with their homologous sera. Moreover, antigen is present in the supernatant of infected ceils as well as the cellular fractions indicating that domain exchange between these molecules is not incompatible with the folding required for correct intracellular transport and secretion, unlike N 7 8,9 10,11 12,1 2 3 6,5 4 C The numbering system represents the order in which the oligonucleotides were made and does not follow any sequence-specific pattern. The designation of each SF mutation is shown on the left side and reflects the oligonucleotides used to generate the fragment for transposition, e.g. SF5,4 indicates a molecule that is wholly HIV-2 gpl05 except for the sequence between oligonucleotides 5 and 4 which is derived from HIV-1 gpl20. Similarly, SFN4 is a molecule that has gpl20 sequence from the N terminus to oligonucleotide 4 with the remainder of the molecule being gp105. In all cases the section of H IV-1 gpl20 sequence within the SF mutant molecule is highlighted with the remainder of the molecule being HIV-2 gpl05. Larger SF mutants and mutants in which there are two sections of gpl20 transposed into the same gpl05 background were constructed by overlapping single exchange mutants via restriction sites within the shared sequence.
some mutations reported in gpl20 (Hemming et al., 1989; Dirckx et al., 1990; Olshevsky et al., 1990) . By similar methods, all our constructions were shown to express and secrete hybrid antigens containing epitopes of both gpl20 and gpl05.
Receptor binding
To investigate receptor binding by our SF hybrids we used the ELISA-based system using sCD4 described elsewhere (Moore, 1990) . We found that SF1,2, in which the V3 loop of gpl05 (HIV-2ROD) was replaced with that of gpl20 (HIV-1LAv), bound to sCD4 with the same efficiency as gpl05 alone and that SF9,10, which replaces the V1 and V2 domains of gpl05 by those of gpl20, also bound to CD4 but with reduced efficiency (Fig. 3 ). All the other SF hybrids detailed in Fig. 1 failed to bind detectably to sCD4. For a number of mutants, binding to cell surface CD4 (as present on CEM-13 cells) was also determined by FACS assay. There was no difference between the results obtained with sCD4 and cell-bound CD4. As the V3 loop exchange of SF1,2 and the V1/V2 loop exchange of SF9,10 did not abolish CD4 binding we conclude that the identity of these variable loops is of little significance for receptor binding. However, given that SF9,10 bound to CD4 with reduced efficiency, a packing effect on the rest of the molecule that can moderate CD4 binding affinity cannot be ruled out and may, in part, explain the observed natural variation in HIV-1 gp 120 biological activity (Ivey-Hoyle et al., 1990) . It is noteworthy that the gpl20 and gpl05 sequences do differ considerably in this region and that the predicted structure of gpl05 includes two extra disulphide bonds compared to gpl20 (Wolf et at., 1991) .
The failure of all other SF constructions to bind CD4 was surprising. In SF5,4 for example, the sequences that are transposed represent one of the regions of highest conservation between gp 120 and gp 105 with 50 ~o amino acid identity. At the other extreme SFN4 represents a molecule that has 90~o identity to gpl20, possessing only a short carboxyl tail derived from gpl05; neither molecule showed measurable CD4 binding. The CD4 binding site on gpl20 or gpl05 is, therefore, likely to be complex and may require distal parts of the same molecule to interact in a sequence-specific manner. If this were true, then complementation between different fractions of the same molecule, as present in each SF construction, to rescue CD4 binding, might occur. Supernatants from all SF mutant infections were tested for CD4 binding ability but only those which scored positive are shown here. Binding curves for all other SF mutants were similar to that shown for the control and no single SF mutant other than SFI,2 and SF9,10 showed any evidence of sCD4 binding under our standard assay conditions. The samples were gpl05 (+), SF1,2 (*), SF9,10 (I-1) and mock-infected control (x).
Trans complementation of CD4 binding
To test for possible complementation of CD4 binding we reassessed CD4 binding after mixing all possible combinations of SF mutant supernatants in vitro and, separately, using supernatants from co-infections of all combinations of SF recombinant viruses. Mixing mutant Complementation experiments were done in 96-well plates using multiplicities of 10 for each recombinant virus. Three days post-infection the supernatant from each well was transferred to a second 96-well plate pre-coated with sCD4 and a single point ELISA was carried out as described (Moore, 1990 ) except that bound antigen was detected with a mixture ofD7335 and D7324 (each at I gg/ml). The grid represents a composite of several experiments. A crossed box indicates sCD4 binding. As the activity recorded depends on the percentage of cells successfully coinfected and the amount of glycoprotein expressed by each recombinant, quantification of CD4 binding relative to each single wild-type molecule is not possible although the pattern of complementation is absolutely reproducible. Therefore we assumed a high cutoff in this assay and only significant (A490 > 0"2) complementation events were scored as positive. The same pairwise mixture of antigens without coinfection gave no complementation of sCD4 binding.
antigen in vitro failed to rescue CD4 binding but coinfected supernatants yielded the complementation pattern shown in Fig. 4 . From 529 co-infection experiments there were 25 unique pair combinations that gave clear CD4 binding. A number of pair combinations also exhibited signals slightly above background that could represent weak complementation but they were not included in the subsequent analysis. Formally, three types of complementation are possible from the mixed infections we have performed: complementation between gpl05 sequences, complementation between gp 120 sequences and complementation between gp 120 and gp 105 sequences. However, given that none of our original SF mutants (with the exception of SF 1,2 and SF9,10) bound to CD4 we consider it unlikely that hybrid CD4 binding sites form in which gpl05 and gpl20 sequences complement each other.
To determine which type of complementation was occurring in CD4-positive supernatants we used the fact that the majority of point mutations in gpl20 known to disrupt receptor binding cluster in the C3 and C4 domains of the molecule (Cys 336 to Asp 462 of gpl20 and Cys 340 to Asp 458 of gpl05) (Dowbenko et al., 1988; Olshevsky et al., 1990 ). This region is also known to be protected from proteolytic degradation when gpl20 is bound by CD4 (Lasky et al., 1987; Nygren et al., 1988) and is clearly an essential part of the CD4 binding site. In co-infections where this domain is derived from the same molecule we deduce that CD4 binding must be typical of the C3-C4 domain donor molecule. For example, in the co-infection SF9C plus SFN10/1C the C3-C4 domain is from gp 120 in both cases and we can consider the rescued CD4 binding to be gpl20-1ike. Similarly, in the coinfection SF7,8 plus SF3,6 the C3 and C4 domains in both cases derive from gpl05 and so we conclude the complemented CD4 site is gpl05-1ike.
In some co-infections, the C3-C4 domain of one of the complementing molecules itself contains mixed antigen (e.g. any molecule with '5,4' in the nomenclature). However, as SF5,4 itself is inactive at binding CD4, complementation involving these SFs must be due to their action in trans on an incoming unmixed C3-C4 region. A good example would be the co-infection SF7,8/5,4 plus SF11C in which the SF7,8 domain of the former complements the 11C domain of the latter to give a gp120-like CD4 binding site. Complementation of the gpI05 sequences cannot occur as the C3-C4 region of gpl05 present in SF7,8/5,4 is itself inactive by virtue of the 5,4 mutation. In the co-infection SF7,8 plus SFllC however, complementation to either gpl20-1ike or gpl05-1ike is possible and the nature of the CD4 site reformed must remain ambiguous. By this logic it is possible to group most of the complementing pairs into one of two groups and, within each group, to define the interactive sequences necessary for CD4 complementat/on. We conclude from this analysis that gpl20 can be broken into at least three separate interacting regions. The 7,8 region (amino acids Cys 74 to Cys 119, numbers refer to HIV-1LAV gpl20), the 11,12 region (amino acids Cys 210 to Cys 301) and the 1C region (amino acids Cys 301 to the C-terminal Arg 516). In addition, as the identity of the V3 loop (Cys 301to Cys 336) plays no role in CD4 binding, the active region of the 1C domain may be considered to be Cys 336 to Arg 516. All three domains can be complemented separately. For example, SF 1C plus SFN4 (the latter molecule providing the SF7,8 and 11,12 domains in trans) and SF7,8/1C plus SF9,4 (SF9,4 providing only the 11,12 domain in trans). However co-infections in which the 11,12 and 1C domains were contiguous (such as those involving SF11C) were much more easily complemented than coinfections in which only the 11,12 domain (as in SF11,4) or IC domain (as in SF1C) were separate (six complementation events for SFllC with the panel of SFs compared with two for SF1C and one for SFll,4; compare with Fig. 4) . Although all three complementing areas can be separated, it appears that CD4 binding is more favourable if the terminal 60 % of the molecule (Cys 210 to Arg 516) remains unchanged.
Nature of the complementing molecule
In theory, the complementation of CD4 binding that we observe could be the result of recombination during the co-infections to generate complete genes of either gp 120 or gpl05. However, the recombination rate in baculovirus-infected cells is typically 0-01 to 0-1% of the progeny virions (Summers & Smith, 1987 ) and so does not contribute significantly to the complementation we observe. Besides, a number of SF pairs could recombine to form complete genes (e.g. SF7,8 with SF 1C to produce a complete gpl05gene) yet do not exhibit strong complementation.
As in vitro mixing of the SF supernatants failed to rescue CD4 binding whereas co-infection of the same panel of mutants did, some form of co-assembly of mutant glycoproteins is clearly required for the production of a functional CD4 binding site. In keeping with this, a number of reports have described the oligomerization of gpl20 although they have failed to agree on the type of multimer formed (Rey et al., 1989; Schawaller et al., 1989; Earl et al., 1990; Weiss et al., 1990; Owens & Compans, 1990; Thomas et al., 1991) . Two possibilities for the reconstitution of the CD4 binding site are immediately obvious. In the first, the site required for CD4 binding could be made up of composite surfaces with each complementing molecule contributing one part. In such cases, the active molecule responsible for CD4 binding would be, at least, a heterodimer. In the second, the folding of one of the complementing molecules to form a CD4 binding site could be affected by the presence of a second molecule in the same secretory/folding pathway. In this case, the CD4 contact region would be present on only one monomer but would have been shaped to a precise fit by the co-expressed molecule providing a chaperone function in trans.
To distinguish between these possibilities, we assayed CD4 binding by a complementing pair of SF mutants (SF7,8/5,4 plus SFIlC) which could be distinguished antigenically by antisera specific for their C termini. Fig.  5 shows that, although neither molecule alone bound CD4 (compare with Fig. 4) , the co-infection supernatant showed specific CD4 binding that was detected by both D7324 (gpl20-and SF11C-specific; Fig. 5a ) and D7335 (gpl05-and SF7,8/5,4-specific; Fig. 5b ). We conclude therefore that in this co-infection at least, the active molecule to bind CD4 is a multimer composed of a minimum of one SFllC molecule and one SF7,8/5,4 molecule. We have also confirmed this result by direct ELISA of the complementation-positive supernatant with partner-specific antibodies. This result formally excludes the possibility of the observed complementation being the result of recombination as no recombinant molecule could possess two differing C termini. The fact that a mixed multimer binds CD4 in this instance (and, we assume, in all other successful co-infections) suggests that normal CD4 binding could be achieved by surfaces derived from two adjacent molecules as might be the case within the glycoprotein spike on the virion surface. If this is so then it is possible that the interactive regions defined here may form the surfaces necessary for subunit interaction. Interestingly, mutations in the 7,8 region of gpl20 have been noted to alter the global conformation of the molecule and to reduce CD4 binding (Olshevsky et al., 1990) . Such mutations could be affecting the packing of monomers into the correct multimeric structure or the 7,8 region-directed folding of the remainder of the molecule. Recently, Pollard et al. (1992) have independently shown complementation of gp 120 function using co-expressed fragments of gp 120 which were shown to be covalently connected by disulphide bonds. Interestingly, their immune precipitation experiments suggested that there were relatively few antibodies in polyvalent sera directed towards the 7,8 region (specifically amino acids 88 to 118). This finding would be consistent with this area of gpl20 being internal within the folded molecule or at the interface of adjacent monomers. In the case of complementing pairs of SF mutants shown here it seems likely, although not formally shown, that complementing molecules are similarly linked by disulphide bonds. It has also been shown that oligomers of the surface glycoprotein component of mink cell focus-forming virus are formed of disulphide-linked monomers (Tucker et al., 1991) . That complementation-positive supernatants cannot be generated by simply mixing SF mutants is also in keeping with the requirement for gpl20 monomers to become covalently linked.
Discussion
We have shown that the sequences within the V 1, V2 and V3 loops of gpl05 can be exchanged for those of gpl20 without loss of CD4 binding ability. Extensive variation occurs in each of these loops in all strains of HIV-1 or HIV-2 sequenced (Myers et al., 1991) . It is not surprising therefore that their exact identity is of little significance for CD4 binding, and Pollard et al. (1992) have shown recently that they are dispensable for CD4 binding. Despite this, there does appear to be some selection for features that may have a structural role in these regions. The V3 loop for example varies very little in length amongst HIV strains and the position of the cysteine residues within the V1/V2 loop is conserved despite their appearing to have no role in receptor binding. It is possible these regions provide the packing necessary for the molecule to gain its full complement of bioactivity, such as gp41 contact, despite their lack of involvement in receptor binding. Unlike the V1/V2 and V3 loops, we were not able to transpose the V4 domain of gpl05 (construct SF3,6) and maintain CD4 binding. Deletions within V4 are equally not tolerated without loss of CD4 binding (Pollard et al., 1992) . Although variable and relatively immune to single point mutagenic change (Olshevsky et al., 1990) , this loop lies between the C3 and C4 domains that are intimately involved in CD4 binding. It is likely therefore that this region of the molecule is much more sensitive to subtle conformational changes induced by the loop swaps than are other regions. Alteration of carbohydrate sites in this region for example has been shown to affect receptor binding Dirckx et al., 1991) .
Although the majority of SF mutants did not retain receptor binding ability, binding could be rescued by complementation in trans and the regions necessary for complementation identified. The third and largest domain (region 1C less the V3 loop equals 180 amino acids) identified by these studies corresponds with the Cterminal region of gpl20 identified as necessary for gpl20 binding by earlier studies, i.e. the C3 and C4 regions (Dowbenko et al., 1988; Cordonnier et al., 1989; Olshevsky et al., 1990 ). It appears probable that this domain of the protein contributes the residues necessary for direct contact with CD4. An identifiable similarity with the immunoglobulins lies within this domain and has been suggested to be involved in receptor contact (Kleber-Emmons et al., 1989) . The fact that this relatively large region cannot be split by complementation analysis might suggest the CD4 contact site within this region is made up of distant residues that interact in the tertiary structure. This would be in contrast to the site recognized by gpl20 on CD4 which is a discrete loop that projects from the main body of the protein (Ryu et al., 1990; Wang et al., 1990) . These data would be consistent with the notion that the CD4 binding site on gpl20 is a cleft in which distal residues are drawn together to form the two sides and floor.
In contrast to the C-terminal half of gpl20, the Nterminal half could be split into two independently acting complementation domains (here called 7,8 and 11,12) . Both these domains have been shown previously to contain residues sensitive to mutagenesis but, in the main, alterations of sequence in these regions caused only mild changes in CD4 binding affinity (less than 10-fold compared to greater than 100-fold for mutations within the C3/C4 domain; Olshevsky et al., 1990) . It is conceivable that these domains make up the scaffolding upon which the C3/C4 domain is presented to CD4 or regions of the protein that are required to induce correct folding. The fact that 'good' C3/C4 domains within our SF mutants are linked in cis to 'bad' 7,8 or 11,12 domains yet can still be complemented by a 'good' 7,8 or 11,12 domain provided in trans leads us to favour the former possibility as folding is presumably guided by cis-acting residues. The fact that the complementing pairs remain associated after secretion also suggests that each partner must continue to provide some necessary interaction after folding and secretion have been achieved.
The corollary of gp120 mutations being complemented in trans is that normal gpl20 function might be disrupted in trans, perhaps by compounds modelled on peptide analogues of the interactive 7, 8 region defined here. Therapies based on such an approach would be highly HIV-specific. Further analysis of the nature of the intra-and inter-molecular contacts within gpl20 necessary for CD4 binding should allow this possibility to be tested. 
